The National Heart, Lung, and Blood Institute (NHLBI) awarded The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, a $496,503 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) on September 1, 2024. The grant will fund a 4-year research project to investigate sex and gender influences on inflammation and pain in sickle cell disease. The study has two main objectives: (1) to ascertain sex- and gender-related mechanisms of perimenstrual vaso-occlusive pain episodes, and (2) to determine the therapeutic effectiveness of the contraceptive Depot Medroxyprogesterone Acetate (DMPA) on reducing vaso-occlusive pain episodes and inflammatory biomarkers in females with sickle cell disease. The research aims to provide a scientific basis for new approaches to preventing vaso-occlusive pain episodes in females with sickle cell disease.
Generated 3/4/25, 5:50 AM